SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease ...
PHILADELPHIA--(BUSINESS WIRE)--iECURE, a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver ...
- Treatment with ECUR-506 resulted in a complete clinical response from three months post exposure to the end of study (six months post exposure) - ECUR-506 was generally well tolerated with no ...
PHILADELPHIA--(BUSINESS WIRE)-- iECURE, Inc., a gene editing company focused on the development of mutation-agnostic in vivo gene insertion therapies for the treatment of liver disorders with ...
Virtual KOL Presentation at 12:00 p.m. ET Today SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (ARCT), a commercial messenger RNA medicines company focused on the development of ...
iECURE will also be presenting at the ICIEM Exhibition Booth, September 3-6, 2025, at the Event Hall in the Kyoto International Conference Center, Booth #E. About the OTC-HOPE Study The OTC-HOPE study ...
About the OTC-HOPE Study The OTC-HOPE study is a Phase 1/2 first-in-human clinical trial of ECUR-506 in baby boys with genetically confirmed neonatal onset OTC deficiency and has been cleared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results